PRG-2302 for relapsed or hard-to-treat B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your leukemia must have come back within 12 months of first remission or not responded to initial treatment.
- Your leukemia cells must show CD19 or CD22 markers (a sign that the drug may target them).
- Your bone marrow must have at least 5% of leukemia cells (blasts).
- Your heart, kidneys, and liver must be working well enough.
- You cannot have active infection in your brain or spinal fluid, or other active cancers or serious health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a specific treatment plan (“CAV regimen”) for people with B-cell ALL that has either come back or did not respond to standard treatment. It may help control the leukemia, if you meet the health and safety requirements.
This trial tests a new drug called STR-P004 for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. It aims to see if the drug is safe and can help fight the cancer.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.